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mediates cardioprotection via Epac1-
dependent signaling
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Abstract
Background: Obesity is still considered a risk factor for cardiovascular disease, although more recent knowledge
also suggests obesity to be associated with reduced morbidity and mortality - the “obesity paradox”. This study
explores if long-term feeding of an obesogenic high fat diet renders the myocardium less susceptible to
ischemic-reperfusion induced injury via Epac-dependent signaling.
Methods: Wild type (wt), Epac1 (Epac1−/−) and Epac2 (Epac2−/−) deficient mice were fed a high fat (HFD) or
normal chow diet (ND) for 33 ± 1 weeks. Six experimental groups were included: (1) control wt ND (wt ND),
(2) control wt HFD (wt HFD), (3) Epac1−/− mice on ND (Epac1−/− ND), (4) Epac1−/− mice on HFD (Epac1−/− HFD), (5)
Epac2−/− mice on ND (Epac2−/− ND), and (6) Epac2−/− mice on HFD (Epac2−/− HFD). Isolated ex vivo mice
hearts were perfused in a constant pressure Langendorff mode, and exposed to 30min of global ischemia
(GI) and 60min of reperfusion. Endpoints were infarct size and functional recovery.
Results: All groups fed a HFD presented with significantly enhanced body weight, visceral fat content and
reduced glucose clearance compared to corresponding ND groups. Although the HFD cohorts presented with an
overall comparable systemic capability to clear glucose, the Epac1−/− HFD group presented with glucose levels slightly
above the human diabetes criteria at the end of the intraperitoneal glucose tolerance test (ipGTT). Moreover, the HFD
significantly reduced infarct size in both wild type (wt HFD 41.3 ± 5.5% vs. wt ND 58.0 ± 9.8%, p < 0.05) and Epac2−/−
cohorts (Epac2−/− HFD 34.4 ± 7.2% vs. Epac2−/− ND 56.5 ± 3.8%, p < 0.05). Interestingly, however, the HFD did not
reduce infarct size in Epac1−/− deficient mice hearts (Epac1−/− HFD 65.1 ± 5.1% vs. Epac1−/− ND 56.1 ± 3.5%, ns.).
Conclusion: Epac1-dependent signaling is involved in mediating the cardioprotection afforded by long-term feeding
of an obesogenic high fat diet in mice hearts.
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Background
Obesity serves as a prevalent risk factor for cardiovascular
disease, and chronic consumption of fat has traditionally
been associated with increased risk for arteriosclerotic
cardiovascular disease such as acute myocardial infarction
(AMI) [1–5]. More recent observations have, however, sug-
gested that human obesity combined with ischemic
heart disease is associated with reduced morbidity
and mortality, the so-called “obesity paradox” [6–10].
Despite intense investigations, the precise mecha-
nism(s) underlying this paradox is complex and
remains to be fully elucidated.
Recent data imply that an obesogenic high fat diet en-
hance myocardial tolerance against ischemic-reperfusion
induced injury (IR), but this cardioprotection was not
associated with activation of ERK p44/p42 or PKB/Akt
dependent RISK signaling (reperfusion injury salvage
kinase pathway) [11], a pathway widely accepted to
mediate protection against reperfusion injury [12, 13].
Furthermore, a recent study by Salie et al. suggests that
hearts protected by obesogenic diets are unresponsive to
additional cardioprotective conditioning maneuvers,
such as ischemic preconditioning (IPC) or β-adrenergic
preconditioning (β-PC), indicating that the hearts were
maximally protected by the diets [11]. Both IPC and
β-PC may elicit protection against IR induced injury via
the β-adrenergic cAMP - PKA signal transduction path-
way [14–16]. Whether β-adrenergic signaling is involved
in mediating high fat diet induced cardioprotection is
currently unknown.
Most of the cardiac effects of β-adrenergic cAMP signal-
ing were assigned to PKA, until de Rooij et al. [17] and
Kawasaki et al. [18] identified the Epac proteins (Exchange
Proteins directly Activated by cAMP; Epac1 and Epac2; also
called cAMPGEFs), which have proven to be important
downstream mediators of cAMP in multiple physiological
pathways. When Epac binds cAMP, it acts as an exchange
factor for the small G-proteins Rap1 and Rap2, catalysing
the exchange of bound GDP for GTP, subsequently activat-
ing a wide array of effectors [19]. In the heart, Epac has
been shown to play a role in Ca2+-handling and excitation-
contraction coupling via phospholipase C, CaMKII, and
PKC dependent signaling [20–23]. Furthermore, studies
aiming at direct pharmacologic activation of Epac using the
cAMP analogue 8-CPT (8-pCPT-2’-O-Me-cAMP), that
discriminates between PKA and Epac in vitro [24], have in-
criminated Epac in cardiac hypertrophy and heart failure
[25, 26], in addition to protecting from IR-induced kidney
injury [27]. Whether Epac-dependent signaling may
contribute towards elevated myocardial tolerance against
IR- induced injury in the heart is currently unknown and
needs further elucidation.
In the present study, we assessed whether long-term
feeding of an obesogenic high fat diet may enhance
tolerance against ischemic-reperfusion induced injury in
the murine heart. Furthermore, we also aimed to delin-
eate whether Epac, a downstream mediator of β-adrener-
gic/cAMP mediated signaling, is involved in diet-
induced cardioprotection. Due to the low stability of
cAMP analogs (including 8-pCPT-2’-O-Me-cAMP) and
Epac inhibitors in vivo (recently reviewed in [28]), we
employed mice deficient in Epac1 and Epac2 in this
study. Here we report that wild type mice exposed to
long-term consumption of a HFD exhibited enhanced
cardiac tolerance against IR-induced injury without any
adverse effects on cardiac function. Importantly, HFD
induced protection was lost in Epac1 deficient mice,
implicating an important role for Epac1- dependent
signaling in HFD induced cardioprotection.
Methods
Animals
Fifty-two female mice of the following genotypes were
included in this study: 24 wild type (wt), 12 Epac1−/−
and 16 Epac2−/−. Artificial lighting was maintained on
a 12:12-h light-dark cycle, room temperature kept at
22 ± 1 °C and the animals provided with water and
food ad libitum. The Epac-deficient mouse models
used in this study are described in detail elsewhere
[29]. In short, loxP sites were inserted by homologous
recombination into the genes encoding Epac1
(RapGEF3) and Epac2 (RapGEF4) flanking exons
7–10 in RapGEF3 and exons 12–13 in RapGEF4.
These exons encode the cAMP-binding domain in
both proteins. A Neomycin cassette flanked by frt-
sites were used for screening purposes and thereafter
excised. Epac1floxed/floxed and Epac2floxed/floxed mice
were generated at the Mouse Clinical Institute, Stras-
bourg, France. In this study, mice globally deleted for
Epac1 (Epac1−/−) or all isoforms of Epac2 (Epac2−/−)
were produced by crossing floxed animals with mice
expressing Cre recombinase from the cytomegalovirus
(CMV)-promoter. The mice were bred against a
C57BL/6JBomTac (Taconic, Denmark) genetic back-
ground for at least ten generations by the start of the
study. Epac1−/− and Epac2−/− mice are healthy and
apparently indistinguishable from wt mice under
standard housing. The wild type C57BL/6JBomTac
animals included were littermates and commercial
mice (Taconic, Denmark). Both Epac1 and Epac2 are
expressed in hearts of wild type (wt) mice, and there
are no compensatory increase in expression of cardiac
Epac1 in Epac2−/− mice or Epac2 in Epac1−/− mice in our
mice models (results not shown).
Biochemical analyses/Biometric analysis
Intraperitoneal glucose tolerance tests (ipGTT) were
performed at baseline (before the start of the feeding
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experiments) and at 28 weeks into the feeding ex-
periment. In brief, animals were fasted overnight
(15 h) before administration of an intraperitoneal
glucose solution (D-glucose, 2 g/kg) followed by
blood sampling from the exposed saphenous vein.
Blood glucose concentration was measured at 0, 15,
30, 60, 90, 120 and 240 (where applicable) minutes
with a glucometer (Precision Xceed, Abbott Labora-
tories). At the end of the feeding experiment, the
peri-gonadal (gWAT) and peri-renal (rWAT) fat was
removed by dissection, performed similarly in all
mice, to obtain a proportional (relative) estimate of
the amount of visceral retroperitoneal fat in the ani-
mals. Similarly, the inguinal fat was removed to rep-
resent the subcutaneous fat depot.
Feeding protocol and experimental groups
All mice received a regular chow diet (ND), until they
were randomly divided into one of two feeding regimes
for 33 ± 1 weeks: regular chow diet (ND) (Special Diets
Services, RM1 801151; 75.1% calories from carbohy-
drate, 17.5% calories from protein and 7.4% calories
from fat) vs. high fat diet (HFD) (Research Diets,
D12492; 20% calories from carbohydrate, 20% of calories
from protein and 60% calories from fat). Four animals
were housed in each cage, giving rise to a total of six
groups (Fig. 1a): (1) wild types (wt) subjected to a ND
throughout the experiment (wt ND), (2) wild types (wt)
subjected to a HFD (wt HFD), (3) Epac1−/− animals sub-
jected to a ND (Epac1−/− ND), (4) Epac1−/− subjected to
a HFD (Epac1−/− HFD), (5) Epac2−/− animals subjected
to a ND (Epac2−/− ND), and (6) Epac2−/− subjected to a
HFD (Epac2−/− HFD).
Isolated Langendorff mouse heart perfusion
Mice were intraperitoneally heparinized (500 IU) and
anesthetized with pentobarbital (50 mg/kg). The hearts
were excised from the thoracic cavity, placed in ice-cold
Krebs-Henseleit buffer (KHB) containing (mM): 118
NaCl, 4.7 KCl, 1.8 CaCl2 x 2 H2O, 1.2 KH2PO4, 1.2
MgSO4 x 7 H2O, 25.2 NaHCO3, 11.0 d-Glucose. Aorta
was immediately cannulated and the mice hearts retro-
gradely perfused in Langendorff modus with warm (37 °C),
gassed (95% O2/5% CO2, pH 7.4) KHB at constant pressure
(70 mmHg). To monitor heart rate (HR) and ventricular
pressures, a fluid-filled balloon-tipped pressure catheter
connected to a high performance data acquisition system
(PowerLab 8/30, Chart Pro software-MLS250) via a hydro-
static pressure transducer (SP844, Memscap, Norway), was
inserted into the left ventricle via the left atrium. The left
ventricular end-diastolic pressure (LVEDP) was set to 5–
10 mmHg at the start of the experiment. Left ventricular
developed pressure (LVDP = LVSP − LVEDP), maximum/
minimum derivative of left ventricular pressure develop-
ment (LVdP/dtmax and LVdP/dtmin; mmHg/s), rate pressure
product (RPP =HR x LVDP (bpm x mmHg); a measure of
internal workload or hemodynamic response, an indicator
of myocardial oxygen demand (MVO2)) and coronary flow
(CF; ml/min) was recorded throughout the experiment.
The Langendorff perfused ex vivo mice hearts were
subjected to an experimental protocol of 110min; 20min of
stabilization followed by 30min of global ischemia (GI) and
60min of reperfusion (Fig. 1b). Hearts with aortic cannula-
tion time > 3min, CF < 1 ml/min and > 5.0 ml/min,
LVSP < 70 mmHg or > 20min of irreversible arrhyth-
mias (asystole or ventricular fibrillation) during reper-
fusion were excluded from the study. A total of 9 hearts
were excluded for the following reasons: 3 hearts due to
CF > 5.0 ml, 2 due to LVSP < 70 mmHg, 3 due to arrhyth-
mias, and one due to improper staining.
Infarct size determination
At the end of the perfusion protocol the mice hearts
were weighed, frozen at −4 °C for 1 h, and cut in 1 mm
thick slices using a stainless steel matrix slicer (Alto,
Angthos). The heart slices were thereafter stained for
12min at 37 °C using 1% triphenyltetrazolium chloride
(TTC; Sigma Chemicals) in phosphate buffer (pH 7.4) to
demarcate the viable from non-viable tissue. To enhance
the contrast of the stain, the slices were submerged in
4% formalin for 1min, and subsequently scanned at high
resolution (2400 dpi, Epson Perfection 4490 Photo).
Photoshop-based image analysis (Adobe Photoshop) was
used in combination with a digitalised tracing board
(Cintiq 13”HD, Wacom) to determine the infarct size,
which was expressed as percent of the area at risk (risk
volume), which for global ischemia is the whole heart
(total ventricular volume, minus cavity spaces).
Fig. 1 Feeding regiment and experimental protocol. a Wild type
(wt), Epac1−/− and Epac2−/− mice were divided into 6 groups exposed
to either a normal chow diet (ND) or a high fat diet (HFD) for
33 ± 1 weeks. One intraperitoneal glucose tolerance test (ipGTT)
was performed before start of the feeding experiment (baseline)
and another 28 weeks into the feeding protocol. b At the end
of the feeding experiment, the hearts were excised and mounted in a
Langendorff perfusion system. Hearts were stabilized for 20min, before
being subjected to 30min global ischemia (GI) and 60min of
reperfusion (Rep)
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Statistics
All statistical analysis was performed using IBM SPSS
Statistics, and the results expressed as mean ± standard
error of the mean (SEM). Group differences regarding
weights, AUC, infarct size and hemodynamic recordings
were tested by one-way analysis of variance (ANOVA)
combined with Fisher’s post-hoc test. p values ≤ 0.05 was
considered statistically significant.
Results
Biometric parameters
The three mice cohorts subjected to long-term high fat
feeding (HFD) presented with significantly (p < 0.05)
higher body weight (BW), HW/BW ratio, total and
visceral fat content than the age-matched controls fed a
normal chow diet (ND) (Table 1). Furthermore, the heart
weight of the Epac1−/− HFD group was significantly higher
than the corresponding Epac1−/− ND, the wt HFD and the
Epac2−/− HFD (Table 1). Despite this, the left ventricular
(LV) volume did not differ between the groups. Moreover,
the HW/BW of the Epac1−/− ND were significantly higher
than wt ND and the Epac2−/− ND.
Glucose dynamics
An intraperitoneal glucose test (ipGTT) before HFD
feeding revealed similar glucose dynamics for all cohorts
(Fig. 2a, left panel). However, the Epac2−/− group had
slightly elevated blood glucose levels for the first 30min
after injection, but their glucose level returned more
rapidly to baseline, resulting in similar area under the
curve (AUC) values for all groups (Fig. 2a, right panel).
Towards the end of the experimental feeding protocol
(28 weeks), all genotypes exposed to long-term feeding of
an obesogenic high fat diet had reduced ability to clear glu-
cose and increased AUC as compared to the ND groups
(Fig. 2b and c, left and right panels). The fasting blood glu-
cose levels (0min) were significantly higher in the obese
HFD groups as compared to the ND cohorts (wt HFD 7.4
± 0.4 mmol/L vs. wt ND 5.2 ± 0.4 mmol/L, p < 0.05) (Epac1
−/− HFD 7.7 ± 0.5 mmol/L vs. Epac1−/− ND 4.3 ± 0.2 mmol/
L, p < 0.05) (Epac2−/− HFD 6.5 ± 0.3 mmol/L vs. Epac2−/−
ND 3.2 ± 0.1 mmol/L, p < 0.05) (Fig. 2b and c, left panels).
These data implicate that only the Epac2−/− HFD group
and the ND groups had euglycemic fasting blood glucose
levels based on the human criteria for diabetes (≤7.0 mmol/
L) (Fig. 2b and c, left panels). Furthermore, all groups fed a
ND had glucose levels well within the euglycemic range
(>7.8 mmol/L) at the end (120min) of the ipGTT. However,
the Epac1−/− HFD group (12.5 mmol/L) had glucose levels
exceeding the human criteria for diabetes (>11.1 mmol/l),
while the wt HFD (11.0 mmol/L) and Epac2−/− HFD
(7.8 mmol/L) can be considered as pre-diabetics with glu-
cose levels between 7.8 and 11.0 mmol/L. After 240min,
the blood glucose levels in all the HFD cohorts returned to
normoglycemic levels (>7.8 mmol/L). The animals in the
HFD cohorts had impaired glucose tolerance (longer
time to clear a given amount of glucose), indicating
deranged glucose homeostasis and reduced insulin
sensitivity (Fig. 2b and c, right panels).
Infarct size
In order to evaluate if long-term feeding of a HFD may
exert cardioprotective properties, we subjected ex vivo
Table 1 Biometric data
Wt
ND
Wt
HFD
Epac1−/−
ND
Epac1−/−
HFD
Epac2−/−
ND
Epac2−/−
HFD
N 8 16 6 6 6 10
BW (g) 27.5 ± 1.6 44.5 ± 2.0& 24.2 ± 0.5 48.4 ± 1.1& 24.7 ± 0.6 38.8 ± 3.0&
HW (mg) 146.3 ± 8.2¤ 162.2 ± 6.7¤ 154.3 ± 8.6¤ 197.7 ± 6.0& 126.5 ± 7.2¤ 137.4 ± 5.3¤
HW/BW (mg/g) 5.3 ± 0.2€ 3.7 ± 0.2& 6.4 ± 0.4 4.1 ± 0.2& 5.2 ± 0.3€ 3.6 ± 0.2 &
LV volume (mm3) 108.6 ± 6.7 117.5 ± 5.2 96.8 ± 4.8 124.7 ± 8.8 96.0 ± 5.4 104.9 ± 2.7
Total fat (g) 1.7 ± 0.3 7.7 ± 0.5& 1.2 ± 0.1 8.6 ± 0.4& 1.1 ± 0.1 6.9 ± 0.7&¤
iWAT (g) 0.4 ± 0.1 2.0 ± 0.1& 0.3 ± 0.1 1.8 ± 0.1& 0.4 ± 0.1 1.9 ± 0.2&
rWAT (g) 0.5 ± 0.1 2.1 ± 0.2& 0.3 ± 0.1 2.5 ± 0.2& 0.3 ± 0.1 2.0 ± 0.2&
gWAT (g) 0.8 ± 0.2 3.6 ± 0.3& 0.6 ± 0.1 4.3 ± 0.2& 0.5 ± 0.1 3.0 ± 0.3&¤
rWAT + gWAT (g) 1.3 ± 0.2 5.7 ± 0.4& 0.9 ± 0.1 6.8 ± 0.3& 0.8 ± 0.1 5.1 ± 0.5&¤
Visceral fat (% of BW) 4.6 ± 0.8 12.5 ± 0.5& 3.4 ± 0.5 14.1 ± 0.4& 3.4 ± 0.2 12.1 ± 0.7&
Body fat (% of BW) 6.1 ± 1.0 17.0 ± 0.5& 4.7 ± 0.4 17.8 ± 0.5& 4.6 ± 0.4 16.7 ± 1.0&¤
Values represent means ± s.e.m
ND normal diet, HFD high fat diet, iWAT inguinal fat (subcutaneous fat), rWAT peri-renal fat, gWAT peri-gonadal fat, rWAT + gWAT visceral fat. &p < 0.05 vs. corresponding
genotype on ND; €p < 0.05 vs. Epac1−/− ND; ¤p < 0.05 vs. Epac1−/− HFD
Body and fat weights were measured at the end of the feeding protocol, while the heart weight was measured after the ex vivo perfusions. Left ventricular (LV)
volume was determined during the infarct size assessment
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mice hearts to 30min of global ischemia (GI) and 60min
of reperfusion at the end of the feeding protocol (See
Fig. 1a for feeding protocol and 1B for perfusion proto-
col). Infarct size, expressed as % of the ventricle, was sig-
nificantly smaller in the wt obese (HFD) group
compared to the wt normal diet (ND) group (wt HFD
41.3 ± 5.5% vs. wt ND 58.0 ± 9.8%, p < 0.05) (Fig. 3). Fur-
thermore, to investigate if absence of Epac1 or Epac2
has an impact on IR-induced injury, we compared Epac1
−/− and Epac2−/− mice to wt mice. Obese Epac2−/− HFD
mice had significantly smaller infarct size than the corre-
sponding Epac2−/− ND control group (Epac2−/− HFD
34.4 ± 7.2% vs. Epac2−/− ND 56.5 ± 3.8%, p < 0.05). In
contrast, the Epac1−/− mice had, if anything, larger in-
farcts when fed a HFD as compared a regular diet
(Epac1−/− HFD 65.1 ± 5.1% vs. Epac1−/− ND 56.1 ± 3.5%,
ns) (Fig. 3). Taken together, these results imply that
Epac2 is not essential, but Epac1 may be required for
the cardioprotection induced by long-term feeding of an
obesogenic high fat diet.
Cardiac functional recovery
The post-ischemic coronary flow (CF) did not show
consistent differences between the three genotypes,
whether fed a normal or high fat diet (Fig. 4a-c),
although wt HFD and Epac2−/− HFD had borderline sig-
nificantly elevated post-ischemic CF as compared to
their corresponding ND groups (Fig. 4a and c).
All groups had significantly (p < 0.05) reduced post-
ischemic rate-pressure product (RPP) compared to their
corresponding stabilization value (Fig. 5a-c). There were
no significant differences in RPP at reperfusion between
the corresponding genotypes fed a ND versus a HFD
a
b
c
Fig. 2 Glucose tolerance test after long-term feeding of an obesogenic high fat diet. Blood glucose levels during an intraperitoneal glucose tolerance
test (ipGTT) in wild type (wt), Epac1 deficient (Epac1−/−) and Epac2 deficient (Epac2−/−) mice; before initiation of the feeding experiment (baseline)
(a, left panel), and after 28 weeks of exposure to either a normal chow diet (ND) or a high fat diet (HFD) in Epac1−/− (b, left panel) and Epac2−/− mice
(c, left panel). The area under the curves (AUC) indicate the total blood glucose variation during the ipGTT (a-c, right panels). Values are mean ± SEM.
*p < 0.05 vs. wt ND. €p < 0.05 vs. Epac1−/− ND. ¤p < 0.05 vs. Epac1−/− HFD. $p < 0.05 vs. Epac2−/− ND. £p < 0.05 vs. Epac2−/− HFD
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(Fig. 5a-c), although RPP in the wt HFD tended to be
higher than in the wt ND group (Fig. 5a).
An elevated left ventricular end-diastolic pressure
(LVEDP) indicate impaired contractility of the heart (con-
tracture), presumably due to compromised calcium hand-
ling that may cause myocardial stunning, which subsides
with prolonged reperfusion. LVEDP in the wt ND group
was significantly (p < 0.05) elevated as compared to wt
HFD and Epac2−/− HFD during the 60min post-ischemic
reperfusion period (Fig. 6a and c), in addition to being sig-
nificantly higher than the corresponding pre-ischemic wt
ND stabilization value (Fig. 6a). LVEDP in the Epac2−/−
ND group were significantly different from wt ND at 5
and 15min of reperfusion (Fig. 6a and c). There are no
differences in LVEDP between the ND and HFD within
the Epac1−/− groups or within the Epac2−/− groups during
the reperfusion period (Fig. 6b and c).
All cohorts, except for the Epac2−/− groups, presented
with significantly (p < 0.05) reduced post-ischemic left
ventricular developed pressure (LVDP) as compared to
their corresponding stabilization values (Table 2). In
regards to the maximum derivative of left ventricular
pressure development (LV dP/dtmax), the wt groups and
the Epac−/− ND showed a significantly lower post-
ischemic recovery compared to their corresponding
stabilization value (Table 2). We did not find any major
differences between the groups in regards to HR and LV
dP/dtmin, except that the Epac1
−/− HFD group only had
a significantly depressed LV dP/dtmin at 60min of reper-
fusion as compared to the corresponding stabilization
value (Table 2).
Discussion
Our findings can be summarised as follows: (1) Long-term
feeding of a high-fat obesogenic diet (HFD) in wt mice in-
creased their tolerance against ischemic-reperfusion (IR)
induced injury, by significantly reducing infarct size in the
ex vivo perfused mice heart. (2) The HFD did not afford
cardioprotection in Epac1−/− mice hearts, indicating
involvement of Epac1-dependent signaling in HFD in-
duced cardioprotection. (3) Epac2−/− mouse hearts were,
like those from wt animals, protected by long-term
feeding of an obesogenic HFD. (4) The HFD intervention
was not associated with compromised post-ischemic
cardiac function or coronary flow.
An obesogenic high fat diet enhances the tolerance
against IR-induced injury
Our findings, summarized above, show that wt mice fed
a HFD become more tolerant to acute myocardial
Fig. 3 Myocardial tolerance to ischemia-reperfusion (I/R) injury after
long-term feeding of an obesogenic high fat diet. Wild type (wt), Epac
1 (Epac1−/−) and Epac 2 (Epac2−/−) deficient mice were exposed to
long-term feeding of either a normal chow diet (ND) or a high
fat diet (HFD). At the end of the feeding protocol, the excised
mice hearts were subjected to global ischemia (GI, 30min) and
reperfusion (Rep, 60min) in a Langendorff perfusion model. Infarct size
is expressed as percentage of the region at risk of infarction. Values are
mean ± SEM and n≥ 6. The numbers given in the figure indicate
significance levels
a
b
c
Fig. 4 Coronary flow in the ex vivo perfused mice hearts. The coronary
flow (CF) were registered after long-term feeding of a normal chow diet
(ND) versus a high fat diet (HFD) in: a wild type (wt), b Epac1 deficient
(Epac1−/−) and c Epac2 deficient (Epac2−/−) mice hearts. Values are
mean ± SEM. *p < 0.05 vs. wt ND. £p < 0.05 vs. Epac2−/− HFD. #p < 0.05
vs. corresponding pre-ischemic stabilization value
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ischemia. They are, thus, in line with recent human
studies documenting reduced morbidity and mortality
when investigating the impact of obesity on ischemic
heart disease [9, 10, 30]. This “obesity paradox” is more
frequently observed in the older patient population, co-
inciding with enhanced age-related risk of ischemic
heart disease [31]. The paradox has also been described
in type 2 diabetic patients with cardiovascular co-
morbidity, in whom overweight and obesity may en-
hance survival in a setting of insulin-resistant diabetes
[32]. Animal studies have confirmed the increased resist-
ance to ischemic heart injury in obese, as well as lean,
type 2 diabetic rats and rabbits [33–35], as well as in rats
[11] and mice fed a HFD [36, 37]. Despite these findings,
the existence and relevance of obesity-dependent cardio-
protection remains controversial. Thus, other studies
show increased myocardial susceptibility in mice with
HFD-induced obesity [38, 39]. The conflicting results
suggest that the effect of HFD-induced obesity may de-
pend on subtle differences between the baseline activity
and “setting” of signalling pathways at the time when is-
chemic stress is applied. There is little evidence that
obesity acts on signaling pathways to promote cell
survival. Obesity may, however, diminish the endothelial
leakage with interstitial oedema formation, which is a
major component of IR-injury (recently reviewed in
[40]), through an increase of the signalling substance
sphingosine 1 phosphate (S1P). S1P is increased in
plasma of obese humans, genetically obese ob/ob mice
and mice fed HFD [41]. Together with cAMP, S1P also
mediates endothelial barrier tightening (reviewed in
[42–45]). In addition, S1P has an acute cardioprotective
effect in an in vivo murine IR-injury model [46] and has
been found essential for successful ischemic postcondi-
tioning in the mouse heart [47].
Epac1 mediates HFD induced cardioprotection
S1P and cAMP act together to maintain the endothelial
barrier [42–45]. If endothelial junctional intactness is
critical for the observed cardioprotection by HFD one
will expect that deletion of Epac1, which maintains the
endothelial barrier in vivo at basal S1P concentration
a
b
c
Fig. 6 Cardiac left ventricular end-diastolic pressure in Langendorff
perfused ex vivo mice hearts. Left ventricular end-diastolic pressure
(LVEDP) were registered at stabilization and during the post-ischemic
reperfusion period in hearts exposed to either a normal chow diet
(ND) or a high fat diet (HFD) in: a wild type (wt), b Epac1 deficient
(Epac1−/−) and c Epac2 deficient (Epac2−/−) mice hearts. Values are
mean ± SEM. *p < 0.05 vs. wt ND. #p < 0.05 vs. corresponding
pre-ischemic stabilization value
a
b
c
Fig. 5 Cardiac rate-pressure product in the ex vivo perfused mice
hearts. The rate-pressure product were calculated (RPP = LVSP x HR)
at stabilization and during the post-ischemic reperfusion period in
mice exposed to long-term feeding of a ND or HFD in: a wild type
(wt), b Epac1 deficient (Epac1−/−) and c Epac2 deficient (Epac2−/−)
mice hearts. Values are mean ± SEM. *p < 0.05 vs. wt ND. £p < 0.05 vs.
Epac2−/− HFD. #p < 0.05 vs. corresponding pre-ischemic
stabilization value
Edland et al. Nutrition & Metabolism  (2016) 13:87 Page 7 of 11
Table 2 Hemodynamic parameters
Group Stab 5’ rep 15’ rep 30’ rep 45’ rep 60’ rep Number
LVDP (mmHg) wt ND 101 ± 7 56 ± 13# 63 ± 7# 56 ± 4# 54 ± 5# 51 ± 4# 8
wt HFD 119 ± 8 94 ± 9# 104 ± 8 95 ± 5* 85 ± 5#,* 74 ± 4# 16
Epac1−/− ND 116 ± 4 72 ± 14# 73 ± 7# 75 ± 8# 77 ± 11# 71 ± 8# 6
Epac1−/− HFD 122 ± 14 89 ± 23# 81 ± 16# 76 ± 15# 82 ± 13# 69 ± 11# 6
Epac2−/− ND 101 ± 8 90 ± 8 92 ± 14 89 ± 12 87 ± 12 88 ± 13 6
Epac2−/− HFD 108 ± 7 81 ± 8 92 ± 12 91 ± 9 80 ± 8 78 ± 9 10
HR (bpm) wt ND 255 ± 22 164 ± 28 173 ± 31 193 ± 29 204 ± 31 208 ± 27 8
wt HFD 260 ± 20 215 ± 24 214 ± 24 196 ± 20$ 195 ± 20 211 ± 24 16
Epac1−/− ND 268 ± 28 269 ± 44 271 ± 42 269 ± 45 272 ± 39 288 ± 39 6
Epac1−/− HFD 288 ± 24 259 ± 57 247 ± 38 254 ± 37 233 ± 43 244 ± 41 6
Epac2−/− ND 300 ± 39 313 ± 41 325 ± 60 338 ± 50 317 ± 51 315 ± 42 6
Epac2−/− HFD 316 ± 29 295 ± 33 280 ± 37 272 ± 27 288 ± 29 286 ± 27 10
dP/dtmin (mmHg/s) wt ND −3926 ± 629 −1287 ± 365
# −1549 ± 334# −1511 ± 308# −1642 ± 248# −1954 ± 646# 8
wt HFD −4973 ± 363 −2742 ± 237# −3096 ± 298# −3024 ± 265#* −2804 ± 239# −2501 ± 183# 16
Epac1−/− ND −4342 ± 325 −2378 ± 512# −2408 ± 271# −2464 ± 209# −2458 ± 270# −2457 ± 244# 6
Epac1−/− HFD −4620 ± 691 −2633 ± 664 −2629 ± 553 −2522 ± 632 −2632 ± 539 −2205 ± 464# 6
Epac2−/− ND −4325 ± 159 −3026 ± 342# −2866 ± 298# −3243 ± 260#* −3106 ± 182# −3284 ± 243# 6
Epac2−/− HFD −5031 ± 715 −2997 ± 659# −3352 ± 601* −3074 ± 390#* −3037 ± 381#* −2771 ± 327# 10
dP/dtmax (mmHg/s) wt ND 6327 ± 997 2701 ± 790
# 3149 ± 648# 2717 ± 368# 2635 ± 297# 2465 ± 355# 8
wt HFD 7195 ± 846 4632 ± 451# 5267 ± 549# 4784 ± 404# 4034 ± 353# 3731 ± 276#$ 16
Epac1−/− ND 7208 ± 923 3486 ± 848# 3590 ± 490# 3875 ± 541# 3287 ± 445# 3414 ± 426# 6
Epac1−/− HFD 6522 ± 1226 4393 ± 1251 3916 ± 922 4038 ± 803 3844 ± 789 3377 ± 795 6
Epac2−/− ND 6958 ± 427 5586 ± 1082 5275 ± 865 5850 ± 310 4934 ± 363 6107 ± 275* 6
Epac2−/− HFD 6808 ± 935 4452 ± 617 5198 ± 771 4742 ± 691 4418 ± 629 4262 ± 661 10
#p < 0.05 vs corresponding pre-ischemic stabilization value, *p < 0.05 vs. wt ND, $p < 0.05 vs. Epac2−/− ND
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[29], will diminish the protective effect of HFD. Since
Epac2 does not affect the endothelial barrier [29], it is
not expected to influence the protective effect of HFD
through increased S1P. Although our results are in line
with HFD protection through endothelial barrier
tightening jointly with cAMP/Epac1, they do not rule
out other possibilities, since Epac1 is expressed in
cardiomyocytes, smooth muscle, and stromal fibro-
blasts [17, 18, 48, 49]. It is also likely that Epac1 is
expressed in the epinephrine-secreting cells, as both
adrenomedullary and chromaffin PC-12 cells express
Epac1 [24].
Many previous studies have focussed on RISK (reper-
fusion injury salvage kinase) signaling as mediator of the
protection against IR-induced injury [12, 13], and several
groups have recently investigated the possible involve-
ment of RISK dependent signaling in diet induced cardi-
oprotection. Du Toit and coworkers showed that
improved myocardial tolerance to IR- induced injury
after 32 weeks of administration of an obesogenic diet
was correlated with increased activation in baseline
PKB/Akt, while they did not report on RISK activation
at reperfusion [50]. However, a recent study by Lochner’s
group did not confirm an association between infarct
size reduction afforded by diet induced obesity and acti-
vation of the pro-survival RISK signaling components
ERK p44/p42 and PKB/Akt [11]. In fact, the protected
HFD group had the lowest activation of ERK and PKB/
Akt at reperfusion. There is therefore no consistent
evidence that HFD protection is primarily through
modulation of the RISK pathway. Additional studies will
have to further delineate the precise role of Epac1 in
HFD induced protection. Mice with endothelial-specific
deletion and ones with cardiomyocyte-specific deletion
of Epac1 will be very useful to pinpoint the primary
locus of the protective action of Epac1.
Preserved contractile function and coronary flow with
dietary high fat obesity
Long-term administration of a high-fat diet to wt mice
improved post-ischemic coronary flow and functional
recovery as compared to the wt ND fed group, corre-
sponding to the reduced infarct size in the wt HFD
group. The Epac2−/− HFD group also presented with im-
proved post-ischemic coronary flow and reduced infarct
size. These data indicates that long-term feeding of an
obesogenic high fat diet does not negatively influence
myocardial contractile function in aged mice hearts,
which are in agreement with experimental studies re-
ported in the literature [11, 51]. However, there are re-
ported discrepancies in terms of whether obesity exerts
deleterious effects or preserves cardiac function. Obesity
is an established independent risk factor for heart failure
[52], though whether obesity directly promotes pump
dysfunction is unknown. Some studies support impair-
ment of systolic function [53, 54], whereas other data
support preserved function in obese humans [55, 56].
Further studies are warranted to fully delineate long-
term functional impact of a high fat diet and obesity on
post-MI functional parameters.
There were no positive impact of feeding a high fat
diet on functional recovery or coronary flow in Epac1-
deficient mice hearts. Coronary flow is regarded as an
important determinant of cardiac function, and it is
possible that the decreased function reflect impaired
flow due to hyperglycemia induced vascular or endothe-
lial dysfunction, in addition to myocyte dysfunction. In
our study, the overall glucose tolerance were comparable
for all the HFD cohorts as indicated by similar AUCs.
However, while there were no significant difference in
the blood glucose levels between the HFD groups at the
end of the ipGTT (120min), the Epac1−/− HFD group
presented with glucose levels slightly above the human
diabetes criteria at this time point. Even so, the Epac1−/−
HFD group did not present with depressed cardiac func-
tion or coronary flow, neither at stabilization nor at
post-ischemic reperfusion, as compared to the corre-
sponding ND control group, thus indicating that the
HFD did not have a detrimental effect on these func-
tional endpoints. It is also noteworthy that the Epac1−/−
HFD hearts had increased heart weight compared to all
other groups, possibly indicating a slight degree of
hypertrophy. Increased muscle mass with reduced
coronary flow could predispose for increased infarct size,
but we do not consider this the main cause for the lack
of cardioprotection in the Epac1−/− HFD hearts, since
both the heart-to-body weight ratio and heart volume
did not differ from the other HFD cohorts.
Conclusion
The results of the present study demonstrate that wild type
mice made obese by long-term feeding of a high fat diet
have enhanced tolerance towards ischemic-reperfusion (IR)
induced injury. Furthermore, the HFD failed to afford car-
dioprotection in Epac1−/− mice hearts, indicating that HFD
mediated cardioprotection require Epac1-dependent signal-
ing, which therefore may implicate a mediating role for
Epac1 in the so called “obesity paradox”.
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